26-A-10902-ACC A PHASE 1 DOSE-ESCALATION AND -EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED SRSD216 IN PATIENTS WITH ELEVATED LIPOPROTEIN(A)
JACC · 2026-04 · 87 (13) · A267
DOI: 10.1016/j.jacc.2026.02.663 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Patrick Yue und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Yue, P., Gu, L., Li, W., Li, H., Dun, Y., pan, J., Tang, Y., & ji, Q. (2026). 26-A-10902-ACC A PHASE 1 DOSE-ESCALATION AND -EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED SRSD216 IN PATIENTS WITH ELEVATED LIPOPROTEIN(A). JACC, 87(13), A267. https://doi.org/10.1016/j.jacc.2026.02.663
Vancouver
Yue P, Gu L, Li W, Li H, Dun Y, pan J, et al. 26-A-10902-ACC A PHASE 1 DOSE-ESCALATION AND -EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED SRSD216 IN PATIENTS WITH ELEVATED LIPOPROTEIN(A). JACC. 2026;87(13):A267. doi:10.1016/j.jacc.2026.02.663
BibTeX
@article{Yue2026,
author = {Yue, Patrick and Gu, Lingling and Li, Weihong and Li, Haiyan and Dun, Yue and pan, jie and Tang, Yida and ji, qunsheng},
title = {26-A-10902-ACC A PHASE 1 DOSE-ESCALATION AND -EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED SRSD216 IN PATIENTS WITH ELEVATED LIPOPROTEIN(A)},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A267},
doi = {10.1016/j.jacc.2026.02.663}
}
EUVIMED